Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2014. The report serves as a notification to the market regarding the company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a capital structure notification and contains no financial performance data.
Material Changes
The filing details the issued share capital as of July 31, 2014:
- Total Issued Ordinary Shares: 5,351,670,128 (25p each)
- Treasury Shares: 502,139,179
- Total Voting Rights: 4,849,530,949
No comparative data for prior periods is included in this specific filing to determine material changes.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to statutory disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (4,849,530,949) for compliance with Financial Conduct Authority disclosure thresholds.
- Confirm the number of shares held in Treasury (502,139,179) to calculate the correct denominator for ownership percentage calculations.
- Note that this filing does not contain operational or financial performance updates; refer to Form 20-F or quarterly earnings releases for such data.